Despite Economic Climate, VC Cash is Available for LS Tool Firms, Say Experts

While the public financing market has virtually dried up and most IPOs have been pulled over recent months, venture capital cash is still available to life science tool firms with innovative products and a compelling business strategy, a couple of venture capital investors told GenomeWeb Daily News.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.